HUTCHMED (China) annual ebitda
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
HUTCHMED (China) EBITDA Growth & History (HCM)
HUTCHMED (China)'s calculated EBITDA was −$25.9M for fiscal 2025.
View full HUTCHMED (China) company overviewHUTCHMED (China) annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$25.9M | $5.5M | — |
| 2024 | 2024-12-31 | −$31.4M | −$57.9M | — |
| 2023 | 2023-12-31 | $26.6M | $425.6M | — |
| 2022 | 2022-12-31 | −$399.0M | −$77.9M | — |
| 2021 | 2021-12-31 | −$321.1M | −$130.5M | — |
| 2020 | 2020-12-31 | −$190.6M | −$49.2M | — |
| 2019 | 2019-12-31 | −$141.4M | −$52.4M | — |
| 2018 | 2018-12-31 | −$89.1M | −$38.2M | — |
| 2017 | 2017-12-31 | −$50.8M | −$6.5M | — |
| 2016 | 2016-12-31 | −$44.4M | −$36.6M | — |
| 2015 | 2015-12-31 | −$7.8M | $9.2M | — |
| 2014 | 2014-12-31 | −$17.0M | — | — |
HUTCHMED (China) quarterly ebitda
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q4 2019 | 2019-12-31 | −$37.1M | −$14.0M | — |
| Q3 2019 | 2019-09-30 | −$34.7M | −$20.8M | — |
| Q2 2019 | 2019-06-30 | −$34.8M | −$7.0M | — |
| Q1 2019 | 2019-03-31 | −$34.8M | −$10.7M | — |
| Q4 2018 | 2018-12-31 | −$23.1M | — | — |
| Q3 2018 | 2018-09-30 | −$13.9M | — | — |
| Q2 2018 | 2018-06-30 | −$27.8M | — | — |
| Q1 2018 | 2018-03-31 | −$24.2M | — | — |
HUTCHMED (China) ebitda trends
Over the last five fiscal years, HUTCHMED (China)'s ebitda increased from −$190.6M to −$25.9M, a change of $164.8M. The latest reported quarter, Q4 2019, shows −$37.1M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review HUTCHMED (China) source filings ↗Community posts
AstraZeneca files US application for lung-cancer combination developed with HUTCHMED
HUTCHMED ($HCM) said AstraZeneca ($AZN) submitted a US new drug application for savolitinib, marketed as ORPATHYS in other jurisdictions, combined with TAGRISSO. The proposed use is MET-driven, EGFR-mutated advanced non-small-cell lung canc ...
